TY - JOUR
T1 - Healthcare-associated infections in adult intensive care unit patients
T2 - Changes in epidemiology, diagnosis, prevention and contributions of new technologies
AU - Blot, Stijn
AU - Ruppé, Etienne
AU - Harbarth, Stephan
AU - Asehnoune, Karim
AU - Poulakou, Garyphalia
AU - Luyt, Charles Edouard
AU - Rello, Jordi
AU - Klompas, Michael
AU - Depuydt, Pieter
AU - Eckmann, Christian
AU - Martin-Loeches, Ignacio
AU - Povoa, Pedro
AU - Bouadma, Lila
AU - Timsit, Jean Francois
AU - Zahar, Jean Ralph
N1 - Funding Information:
JFT declares research grants from Pfizer, Merck, 3M, Astellas, Biomerieux; scientific Board participation with Merck, Bayer pharma, Gilead; lecture fees for Merck, Pfizer, Biomerieux. GP declares Speaker’s Honoraria by Merck, Angellini, Biorad, Pfizer; research grants by Merck, Pfizer, Roche. CE declares scientific board participation and lecture fees for Correvio, Menarini, Merck and Pfizer. PD received fees from Belgian Health Care Knowledge Centre. SH declares SAB fees from Sandoz. SB declares conflict of interest with Pfizer, Halyard and 3M.CEL declares research grants from Bayer Healthcare and Maquet; scientific board participation with Bayer Healthcare, ThermoFischer Brahms, Carmat, Faron; lecture fees from Merck, Biomérieux. JR declares consultancy and speakers bureau fees for Pfizer and Nebriva. MK declares receiving research grants from the US Centers for Disease Control and Prevention and royalties from UpToDate Inc. CE declares scientific board participation and lecture fees for Correvio, Menarini, Merck and Pfizer. IML declares lecture fees from accelerate, MSD and Gilead. PP declares lectures fees from Pfizer and Orion. JRZ declares research grants from Pfizer, Merck; scientific Board participation with Merck, BioMerieux, Eumedica, Pfizer; lecture fees for Merck, Pfizer, Correvio, Gilead. No other conflicts of interests to declare.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/6
Y1 - 2022/6
N2 - Patients in intensive care units (ICUs) are at high risk for healthcare-acquired infections (HAI) due to the high prevalence of invasive procedures and devices, induced immunosuppression, comorbidity, frailty and increased age. Over the past decade we have seen a successful reduction in the incidence of HAI related to invasive procedures and devices. However, the rate of ICU-acquired infections remains high. Within this context, the ongoing emergence of new pathogens, further complicates treatment and threatens patient outcomes. Additionally, the SARS-CoV-2 (COVID-19) pandemic highlighted the challenge that an emerging pathogen provides in adapting prevention measures regarding both the risk of exposure to caregivers and the need to maintain quality of care. ICU nurses hold a special place in the prevention and management of HAI as they are involved in basic hygienic care, steering and implementing quality improvement initiatives, correct microbiological sampling, and aspects antibiotic stewardship. The emergence of more sensitive microbiological techniques and our increased knowledge about interactions between critically ill patients and their microbiota are leading us to rethink how we define HAIs and best strategies to diagnose, treat and prevent these infections in the ICU. This multidisciplinary expert review, focused on the ICU setting, will summarise the recent epidemiology of ICU-HAI, discuss the place of modern microbiological techniques in their diagnosis, review operational and epidemiological definitions and redefine the place of several controversial preventive measures including antimicrobial-impregnated medical devices, chlorhexidine-impregnated washcloths, catheter dressings and chlorhexidine-based mouthwashes. Finally, general guidance is suggested that may reduce HAI incidence and especially outbreaks in ICUs.
AB - Patients in intensive care units (ICUs) are at high risk for healthcare-acquired infections (HAI) due to the high prevalence of invasive procedures and devices, induced immunosuppression, comorbidity, frailty and increased age. Over the past decade we have seen a successful reduction in the incidence of HAI related to invasive procedures and devices. However, the rate of ICU-acquired infections remains high. Within this context, the ongoing emergence of new pathogens, further complicates treatment and threatens patient outcomes. Additionally, the SARS-CoV-2 (COVID-19) pandemic highlighted the challenge that an emerging pathogen provides in adapting prevention measures regarding both the risk of exposure to caregivers and the need to maintain quality of care. ICU nurses hold a special place in the prevention and management of HAI as they are involved in basic hygienic care, steering and implementing quality improvement initiatives, correct microbiological sampling, and aspects antibiotic stewardship. The emergence of more sensitive microbiological techniques and our increased knowledge about interactions between critically ill patients and their microbiota are leading us to rethink how we define HAIs and best strategies to diagnose, treat and prevent these infections in the ICU. This multidisciplinary expert review, focused on the ICU setting, will summarise the recent epidemiology of ICU-HAI, discuss the place of modern microbiological techniques in their diagnosis, review operational and epidemiological definitions and redefine the place of several controversial preventive measures including antimicrobial-impregnated medical devices, chlorhexidine-impregnated washcloths, catheter dressings and chlorhexidine-based mouthwashes. Finally, general guidance is suggested that may reduce HAI incidence and especially outbreaks in ICUs.
KW - Bloodstream infection
KW - Catheter-related infections
KW - Critically ill
KW - Hospital-acquired infection
KW - Infection prevention and control
KW - Intensive care
KW - Multidrug resistance
KW - Pneumonia
KW - Sepsis
KW - Urinary tract infections
KW - Intensive Care Units
KW - Humans
KW - Cross Infection/diagnosis
KW - Catheter-Related Infections
KW - COVID-19
KW - SARS-CoV-2
KW - Delivery of Health Care
KW - Adult
KW - Chlorhexidine
U2 - 10.1016/j.iccn.2022.103227
DO - 10.1016/j.iccn.2022.103227
M3 - Journal article
C2 - 35249794
AN - SCOPUS:85125636675
SN - 0964-3397
VL - 70
JO - Intensive and Critical Care Nursing
JF - Intensive and Critical Care Nursing
M1 - 103227
ER -